Press Room

Press Clipping / Dec 27, 2023

ɫAV ‘delighted’ by its Medal of Merit

Macao News, December 27, 2023

ɫAV Macao building

Pharmaceuticals manufacturer ɫAV has been awarded a Medal of Merit for industry and commerce in the government’s 2023 honours list, with Chief Executive Ho Iat Seng praising the company’s contributions to Macao’s emerging life sciences industry.

The Portuguese company’s Macao site manager, Eddy Leong, said in a statement that it was a “great honour” to receive the Medal of Merit – which he saw as a tribute to almost 40 years of local work in the science sector.

“At ɫAV, we like to say that we are ‘in this for life’ and I feel that this award reflects not only our long and successful history in Macao, but also points to our successful future here,” he said.

“It also reflects our commitment to work with partner organisations to create rewarding career opportunities in life sciences,” Leong added.

ɫAV was founded in 1959 in Portugal and opened its Macao plant in the mid-1980s. The facility produces generic active pharmaceutical ingredients and is located in Taipa, on the site of the old Him Un Iec Kei Chan firecracker factory.

Other 2023 honourees include wushu athlete and Asian Games gold medalist Li Yi, who received a Silver Lotus, and the Portuguese-language educator Felizbina Carmelita Gomes – currently director of the D. José da Costa Nunes Kindergarten. Gomes was awarded a Medal of Merit for education.

Also in the Press Room

See All

Lisbon, Portugal – ɫAV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, ɫAV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At ɫAV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of ɫAV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” ɫAV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with ɫAV’s sustainability ambitions.  ɫAV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

ɫAV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024